ATE355839T1 - 1,4,5-substituierte 1,2-dihydro-pyrazol-3-one and 3-alkoxy-1h-pyrazole derivate als tnf-alpha und interleukin senkende wirkstoffe zur behandlung von entzündungen - Google Patents

1,4,5-substituierte 1,2-dihydro-pyrazol-3-one and 3-alkoxy-1h-pyrazole derivate als tnf-alpha und interleukin senkende wirkstoffe zur behandlung von entzündungen

Info

Publication number: ATE355839T1
Authority: AT; Austria
Prior art keywords: disease; hiv; inflammation; treatment; syndrome
Prior art date: 2002-09-09

Application number

AT03755794T

Other languages

English (en)

Inventor

Celia Dominguez

Dawei Zhang

Kelvin K C Sham

Guo-Qiang Cao

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-09-09

Filing date

2003-09-08

Publication date

2007-03-15

2003-09-08 Application filed by Amgen Inc filed Critical Amgen Inc

2007-03-15 Application granted granted Critical

2007-03-15 Publication of ATE355839T1 publication Critical patent/ATE355839T1/de

Links

206010061218 Inflammation Diseases 0.000 title abstract 2
230000004054 inflammatory process Effects 0.000 title abstract 2
238000011282 treatment Methods 0.000 title abstract 2
XBYRMPXUBGMOJC-UHFFFAOYSA-N 1,2-dihydropyrazol-3-one Chemical class OC=1C=CNN=1 XBYRMPXUBGMOJC-UHFFFAOYSA-N 0.000 title 1
206010001052 Acute respiratory distress syndrome Diseases 0.000 abstract 2
241000701022 Cytomegalovirus Species 0.000 abstract 2
208000013616 Respiratory Distress Syndrome Diseases 0.000 abstract 2
206010040070 Septic Shock Diseases 0.000 abstract 2
208000011341 adult acute respiratory distress syndrome Diseases 0.000 abstract 2
201000000028 adult respiratory distress syndrome Diseases 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 1
208000024827 Alzheimer disease Diseases 0.000 abstract 1
206010002198 Anaphylactic reaction Diseases 0.000 abstract 1
206010002556 Ankylosing Spondylitis Diseases 0.000 abstract 1
201000001320 Atherosclerosis Diseases 0.000 abstract 1
210000002237 B-cell of pancreatic islet Anatomy 0.000 abstract 1
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 abstract 1
206010006895 Cachexia Diseases 0.000 abstract 1
206010063094 Cerebral malaria Diseases 0.000 abstract 1
208000010833 Chronic myeloid leukaemia Diseases 0.000 abstract 1
206010009900 Colitis ulcerative Diseases 0.000 abstract 1
208000011231 Crohn disease Diseases 0.000 abstract 1
206010012442 Dermatitis contact Diseases 0.000 abstract 1
201000005569 Gout Diseases 0.000 abstract 1
206010018634 Gouty Arthritis Diseases 0.000 abstract 1
208000031886 HIV Infections Diseases 0.000 abstract 1
206010020164 HIV infection CDC Group III Diseases 0.000 abstract 1
208000007514 Herpes zoster Diseases 0.000 abstract 1
241000713772 Human immunodeficiency virus 1 Species 0.000 abstract 1
241000713340 Human immunodeficiency virus 2 Species 0.000 abstract 1
208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
208000034578 Multiple myelomas Diseases 0.000 abstract 1
206010028289 Muscle atrophy Diseases 0.000 abstract 1
208000000112 Myalgia Diseases 0.000 abstract 1
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 abstract 1
208000033776 Myeloid Acute Leukemia Diseases 0.000 abstract 1
208000010191 Osteitis Deformans Diseases 0.000 abstract 1
208000001132 Osteoporosis Diseases 0.000 abstract 1
208000027868 Paget disease Diseases 0.000 abstract 1
206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
201000004681 Psoriasis Diseases 0.000 abstract 1
206010037660 Pyrexia Diseases 0.000 abstract 1
208000033464 Reiter syndrome Diseases 0.000 abstract 1
206010063837 Reperfusion injury Diseases 0.000 abstract 1
206010039085 Rhinitis allergic Diseases 0.000 abstract 1
206010040047 Sepsis Diseases 0.000 abstract 1
208000006011 Stroke Diseases 0.000 abstract 1
206010044248 Toxic shock syndrome Diseases 0.000 abstract 1
231100000650 Toxic shock syndrome Toxicity 0.000 abstract 1
208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
230000001154 acute effect Effects 0.000 abstract 1
201000010105 allergic rhinitis Diseases 0.000 abstract 1
230000036783 anaphylactic response Effects 0.000 abstract 1
208000003455 anaphylaxis Diseases 0.000 abstract 1
208000006673 asthma Diseases 0.000 abstract 1
208000019664 bone resorption disease Diseases 0.000 abstract 1
208000010247 contact dermatitis Diseases 0.000 abstract 1
230000006378 damage Effects 0.000 abstract 1
208000015181 infectious disease Diseases 0.000 abstract 1
206010022000 influenza Diseases 0.000 abstract 1
208000012947 ischemia reperfusion injury Diseases 0.000 abstract 1
208000027202 mammary Paget disease Diseases 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
201000006417 multiple sclerosis Diseases 0.000 abstract 1
208000010125 myocardial infarction Diseases 0.000 abstract 1
201000008482 osteoarthritis Diseases 0.000 abstract 1
238000011321 prophylaxis Methods 0.000 abstract 1
208000002574 reactive arthritis Diseases 0.000 abstract 1
206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
230000036303 septic shock Effects 0.000 abstract 1
208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
241000701161 unidentified adenovirus Species 0.000 abstract 1
241001529453 unidentified herpesvirus Species 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Virology (AREA)
Oncology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Immunology (AREA)
Communicable Diseases (AREA)
Neurology (AREA)
Pulmonology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Vascular Medicine (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Transplantation (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Tropical Medicine & Parasitology (AREA)

AT03755794T 2002-09-09 2003-09-08 1,4,5-substituierte 1,2-dihydro-pyrazol-3-one and 3-alkoxy-1h-pyrazole derivate als tnf-alpha und interleukin senkende wirkstoffe zur behandlung von entzündungen ATE355839T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US40917602P	2002-09-09	2002-09-09

Publications (1)

Publication Number	Publication Date
ATE355839T1 true ATE355839T1 (de)	2007-03-15

Family

ID=31978728

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03755794T ATE355839T1 (de)	2002-09-09	2003-09-08	1,4,5-substituierte 1,2-dihydro-pyrazol-3-one and 3-alkoxy-1h-pyrazole derivate als tnf-alpha und interleukin senkende wirkstoffe zur behandlung von entzündungen

Country Status (11)

Country	Link
US (1)	US6967254B2 (de)
EP (1)	EP1542680B1 (de)
JP (1)	JP2006501263A (de)
AT (1)	ATE355839T1 (de)
AU (1)	AU2003273295B2 (de)
CA (1)	CA2497007A1 (de)
DE (1)	DE60312342T2 (de)
ES (1)	ES2283811T3 (de)
MX (1)	MXPA05002513A (de)
PL (1)	PL379544A1 (de)
WO (1)	WO2004022055A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1812071A2 (de) *	2004-10-13	2007-08-01	PTC Therapeutics, Inc.	Verbindungen zur nonsense-unterdrückung und verwendung dieser verbindungen für die herstellung eines medikaments zur behandlung somatischer mutationsbedingter erkrankungen
TW200639163A (en) *	2005-02-04	2006-11-16	Genentech Inc	RAF inhibitor compounds and methods
CA2618068C (en) *	2005-08-05	2016-02-16	Amgen Inc.	Stable aqueous protein or antibody pharmaceutical formulations and their preparation
WO2007035906A2 (en) *	2005-09-21	2007-03-29	The Regents Of The University Of California	Systems and methods for imaging-treatment of pain
US9187455B2 (en) *	2009-02-23	2015-11-17	Hoffmann-La Roche Inc.	Substituted pyridazines as PDE10A inhibitors
DE102011055815A1 (de) *	2011-11-29	2013-05-29	Aicuris Gmbh & Co. Kg	Carboxamid-substituierte Heteroaryl-Pyrazole und ihre Verwendung
WO2013082458A1 (en)	2011-12-02	2013-06-06	The Regents Of The University Of California	Reperfusion protection solution and uses thereof
US20190060286A1 (en)	2016-02-29	2019-02-28	University Of Florida Research Foundation, Incorpo	Chemotherapeutic Methods
CN111067911A (zh) *	2018-10-18	2020-04-28	刘琦	白头翁皂苷b4抗急性痛风性关节炎的医药用途
CN115957218B (zh) *	2021-10-08	2024-11-05	中国医学科学院药物研究所	一种ccr5抑制剂及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS4935278B1 (de) *	1970-09-26	1974-09-20
CA994338A (en)	1973-09-25	1976-08-03	Merck Sharp And Dohme (I.A.) Corp. U.S.A. (Doing Business As Laboratoire S Merck Frosst Laboratories)	Compositions containing heterocyclic bronchodilating agents
JPS5821251B2 (ja) *	1978-08-28	1983-04-28	旭化成株式会社	乾式画像形成材料
IL86926A (en) *	1987-07-13	1992-07-15	Sterling Drug Inc	Diphenyl-1h-pyrazole-1-alkanamides,their preparation and antiarrhythmic compositions containing them
US4898880A (en) *	1989-03-22	1990-02-06	Sterling Drug Inc.	N-(heterocycle)alkyl)-1H-pyrazole-1-alkanamides as antiarrhythmic agents, compositions and use
US5191084A (en) *	1991-05-01	1993-03-02	American Home Products Corporation	Phenyl pyrazolidinones as bronchodilators and anti-inflammatory agents
US5559137A (en) *	1994-05-16	1996-09-24	Smithkline Beecham Corp.	Compounds
US6096753A (en)	1996-12-05	2000-08-01	Amgen Inc.	Substituted pyrimidinone and pyridone compounds and methods of use
US6514977B1 (en) *	1997-05-22	2003-02-04	G.D. Searle & Company	Substituted pyrazoles as p38 kinase inhibitors
PL336990A1 (en) *	1997-05-22	2000-07-31	Searle & Co	3(5)-heteroaryl group substituted pyrazoles as inhibitors of kinase p 38
JP2002502380A (ja) *	1997-05-22	2002-01-22	ジー．ディー．サールアンドカンパニー	ｐ３８キナーゼ阻害剤としてのピラゾール誘導体
US20020156104A1 (en) *	1997-06-13	2002-10-24	Jerry L. Adams	Novel pyrazole and pyrazoline substituted compounds
CA2327185A1 (en) *	1998-04-08	1999-10-14	Abbott Laboratories	Pyrazole inhibitors of cytokine production
US6548529B1 (en) *	1999-04-05	2003-04-15	Bristol-Myers Squibb Company	Heterocyclic containing biphenyl aP2 inhibitors and method
DK1206474T3 (da) *	1999-08-27	2004-10-04	Abbott Lab	Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer
US6821971B2 (en) *	2001-09-20	2004-11-23	The Procter & Gamble Company	Fused pyrazolone compounds which inhibit the release of inflammatory cytokines
US6677337B2 (en) *	2002-03-19	2004-01-13	The Procter & Gamble Company	1,2-dihydropyrazol-3-ones which controls inflammatory cytokines

2003
- 2003-09-08 AT AT03755794T patent/ATE355839T1/de not_active IP Right Cessation
- 2003-09-08 US US10/658,298 patent/US6967254B2/en not_active Expired - Fee Related
- 2003-09-08 ES ES03755794T patent/ES2283811T3/es not_active Expired - Lifetime
- 2003-09-08 AU AU2003273295A patent/AU2003273295B2/en not_active Ceased
- 2003-09-08 WO PCT/US2003/028067 patent/WO2004022055A1/en not_active Ceased
- 2003-09-08 EP EP03755794A patent/EP1542680B1/de not_active Expired - Lifetime
- 2003-09-08 DE DE60312342T patent/DE60312342T2/de not_active Expired - Fee Related
- 2003-09-08 PL PL379544A patent/PL379544A1/pl not_active Application Discontinuation
- 2003-09-08 CA CA002497007A patent/CA2497007A1/en not_active Abandoned
- 2003-09-08 JP JP2004534741A patent/JP2006501263A/ja active Pending
- 2003-09-08 MX MXPA05002513A patent/MXPA05002513A/es active IP Right Grant

Also Published As

Publication number	Publication date
DE60312342D1 (de)	2007-04-19
WO2004022055A1 (en)	2004-03-18
PL379544A1 (pl)	2006-10-02
WO2004022055B1 (en)	2005-01-13
ES2283811T3 (es)	2007-11-01
AU2003273295B2 (en)	2007-03-22
DE60312342T2 (de)	2007-07-12
EP1542680B1 (de)	2007-03-07
EP1542680A1 (de)	2005-06-22
MXPA05002513A (es)	2005-05-27
US6967254B2 (en)	2005-11-22
AU2003273295A1 (en)	2004-03-29
CA2497007A1 (en)	2004-03-18
JP2006501263A (ja)	2006-01-12
US20040058918A1 (en)	2004-03-25

Legal Events

Date	Code	Title	Description
2007-09-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
WO2003099808A8 (en)	2009-02-05	Substituted heterocyclic compounds and methods of use
ATE355839T1 (de)	2007-03-15	1,4,5-substituierte 1,2-dihydro-pyrazol-3-one and 3-alkoxy-1h-pyrazole derivate als tnf-alpha und interleukin senkende wirkstoffe zur behandlung von entzündungen
HRP20050417B1 (hr)	2013-11-08	Antiviralni derivati nukleozida
WO2007070434A3 (en)	2008-03-06	Fused aminopiperidines as dipeptidyl peptidase-4 inhibitors for the treatment or prevention of diabetes
NO2008013I1 (no)	2008-09-08	Sitagliptin, eventuelt i form av et farmasoytisk akseptabelt salt, saerling monofosfatet, pluss metformin, eventuelt i form av et farmasoytisk akseptabelt salt, saerling hydrokloridet
MXPA03011484A (es)	2004-03-18	Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
EP1554280A4 (de)	2006-07-05	Antidiabetische heterocyclische beta-aminoverbindungen als inhibitoren von dipeptidylpeptidase
MA29926B1 (fr)	2008-11-03	Derives de pyrazine
EP1490335A4 (de)	2006-02-08	Heterocyclische beta-aminoverbindungen als inhibitoren der dipeptidylpeptidase zur behandlung bzw. prävention von diabetes
ATE368647T1 (de)	2007-08-15	Pharmazeutische zusammensetzung und ihre verwendung als inhibitoren von der dipeptidyl peptidase iv (dpp-iv)
EA200500304A1 (ru)	2005-10-27	Производные 3-(сульфонамидоэтил)индола, предназначенные для использования в качестве миметиков глюкокортикоидов при лечении воспалительных, аллергических и пролиферативных заболеваний
NO20041631L (no)	2004-05-26	Piperazinderivater med CCR1 reseptor antagonist
MA28747B1 (fr)	2007-07-02	Dérivés de pyridine
MX2008012490A (es)	2008-10-10	Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes.
CL2004000437A1 (es)	2005-06-03	Compuestos heterociclicos del tipo [1,4]-diazepan-2-ona sustituidos, inhibidores de la enzima dipeptidilpeptidasa-iv (cdp-iv); composicion farmaceutica; y su uso para preparar un medicamento para tratar hiperglucemia, diabetes tipo 2, obesidad, trast
ATE544765T1 (de)	2012-02-15	Imidazoä4,5-cüpyridinverbindungen und verfahren zur antiviralen behandlung
ATE527259T1 (de)	2011-10-15	Kondensierte aminopiperidine als dipeptidylpeptidase-iv-inhibitoren zur behandlung oder prävention von diabetes
DE602004018503D1 (de)	2009-01-29	Hexahydrodiazepinone als inhibitoren des dipeptidylpeptidase-iv zur behandlung bzw. prävention von diabetes
WO2006078676A3 (en)	2007-03-29	Bicyclic pyrimidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
HRP20050830A2 (en)	2006-09-30	Non-nucleoside reverse transcriptase inhibitors i for treating hiv mediated diseases
EA200800975A1 (ru)	2008-08-29	ПИРИМИДИНИЛАМИДНЫЕ СОЕДИНЕНИЯ (ВАРИАНТЫ), ВКЛЮЧАЮЩАЯ ИХ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, ОПОСРЕДОВАННОГО α4-ИНТЕГРИНАМИ
DE60326232D1 (de)	2009-04-02	Verwendung von substituierten cyanopyrrolidinen zur behandlung von hyperlipidämie
WO2007114827A8 (en)	2009-01-15	Substituted heterocyclic compounds and methods of use
WO2007083182A3 (en)	2007-11-15	Novel heterocycles
WO2007031829A3 (en)	2007-11-08	Novel pyrimidine carboxamides